Carboplatin plus epirubicin plus VP-16, concurrent 'split course' radiotherapy and adjuvant surgery for limited small cell lung cancer

Cesare Gridelli, Modesto D'Aprile, Carlo Curcio, Luigi Brancaccio, Sergio Palmeri, Giuseppe Comella, Enzo Veltri, Giovanni Ferrante, Maria Gentile, Antonio Rossi, Giorgio Arcangeli, Maurizio Montella, A. Raffaele Bianco

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-three patients with limited small cell lung cancer (SCLC) received carboplatin, epirubicin and VP-16 chemotherapy, concurrent 'split course' thoracic radiotherapy, followed by surgery for patients achieving an objective response (OR). High-risk patients and those staged T4-N3 (IIIB) at diagnosis, were excluded from surgery. After induction chemoradiotherapy we obtained 90.9% OR, with 63.3% obtaining complete response (CR). Ten patients (30.3%) were eligible for surgery after induction therapy. Five patients (15.1%) were subjected to surgery and five additional patients refused. Of the five patients who were subjected to surgery, four had a complete response (CR), (three pathological confirmations), and one had a partial response (PR), (unresectable). The median survival time for all patients was 16 months with 12.1% of the long-term survivors still living after 2 years and 9% still living after 3 and 4 years. Toxicity consisted mainly of myelosuppression. This study shows a high activity of the chemotherapy and the chemoradiotherapeutic regimen employed but a low feasibility for adjuvant surgery in SCLC.

Original languageEnglish
Pages (from-to)83-91
Number of pages9
JournalLung Cancer
Volume11
Issue number1-2
DOIs
Publication statusPublished - 1994

Keywords

  • Combined treatment
  • SCLC
  • Surgery

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Carboplatin plus epirubicin plus VP-16, concurrent 'split course' radiotherapy and adjuvant surgery for limited small cell lung cancer'. Together they form a unique fingerprint.

Cite this